Literature DB >> 33023985

Breast cancer-associated macrophages promote tumorigenesis by suppressing succinate dehydrogenase in tumor cells.

Valentí Gómez1, Thomas R Eykyn2, Rami Mustapha3, Fabián Flores-Borja4, Victoria Male5, Paul R Barber6, Antonia Patsialou6, Ryan Green4, Fani Panagaki2, Chun W Li2, Gilbert O Fruhwirth2, Susana Ros7, Kevin M Brindle7, Tony Ng1,3,4.   

Abstract

Tumor-associated macrophages (TAMs) can exist in pro- and anti-inflammatory states. Anti-inflammatory TAMs (also referred to as M2-polarized) generally suppress antitumor immune responses and enhance the metastatic progression of cancer. To explore the mechanisms behind this phenomenon, we isolated macrophages from mice and humans, polarized them ex vivo, and examined their functional interaction with breast cancer cells in culture and in mice. We found that anti-inflammatory TAMs promoted a metabolic state in breast cancer cells that supported various protumorigenic phenotypes. Anti-inflammatory TAMs secreted the cytokine TGF-β that, upon engagement of its receptors in breast cancer cells, suppressed the abundance of the transcription factor STAT1 and, consequently, decreased that of the metabolic enzyme succinate dehydrogenase (SDH) in the tumor cells. The decrease in SDH levels in tumor cells resulted in an accumulation of succinate, which enhanced the stability of the transcription factor HIF1α and reprogrammed cell metabolism to a glycolytic state. TAM depletion-repletion experiments in a 4T1 mouse model additionally revealed that anti-inflammatory macrophages promoted HIF-associated vascularization and expression of the immunosuppressive protein PD-L1 in tumors. The findings suggest that anti-inflammatory TAMs promote tumor-associated angiogenesis and immunosuppression by altering metabolism in breast cancer cells.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2020        PMID: 33023985     DOI: 10.1126/scisignal.aax4585

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  8 in total

Review 1.  Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated.

Authors:  Keywan Mortezaee; Jamal Majidpoor; Ebrahim Kharazinejad
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

Review 2.  Drug-Tolerant Persister Cells in Cancer Therapy Resistance.

Authors:  Pavan Kumar Dhanyamraju; Todd D Schell; Shantu Amin; Gavin P Robertson
Journal:  Cancer Res       Date:  2022-07-18       Impact factor: 13.312

Review 3.  Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.

Authors:  Yunzhou Pu; Qing Ji
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

Review 4.  TGF-β in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment.

Authors:  Roberta Angioni; Ricardo Sánchez-Rodríguez; Antonella Viola; Barbara Molon
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

5.  Single-cell analysis revealed that IL4I1 promoted ovarian cancer progression.

Authors:  Hongyu Zhao; Yu Teng; Wende Hao; Jie Li; Zhefeng Li; Qi Chen; Chenghong Yin; Wentao Yue
Journal:  J Transl Med       Date:  2021-10-30       Impact factor: 5.531

6.  Uncovering the stability status of the reputed reference genes in breast and hepatic cancer cell lines.

Authors:  Gilar Gorji-Bahri; Niloofar Moradtabrizi; Atieh Hashemi
Journal:  PLoS One       Date:  2021-11-09       Impact factor: 3.240

7.  The paracrine effects of adipocytes on lipid metabolism in doxorubicin-treated triple negative breast cancer cells.

Authors:  Ilze Mentoor; Anna-Mart Engelbrecht; Mari van de Vyver; Paul J van Jaarsveld; Theo Nell
Journal:  Adipocyte       Date:  2021-12       Impact factor: 4.534

Review 8.  TGF-β signaling in the tumor metabolic microenvironment and targeted therapies.

Authors:  Xueke Shi; Jin Yang; Shuzhi Deng; Hongdan Xu; Deyang Wu; Qingxiang Zeng; Shimeng Wang; Tao Hu; Fanglong Wu; Hongmei Zhou
Journal:  J Hematol Oncol       Date:  2022-09-17       Impact factor: 23.168

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.